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Comments on Tegaserod Trial on Irritable 
Bowel Syndrome
TO THE EDITOR:  Irritable bowel syndrome (IBS) remains 
to be a challenge for the gastroenterologist, due to its high preva-
lence and impacts on poor quality of life (QOL) with unsat-
isfactory pharmacological treatments. Most of the current treat-
ment modalities for IBS have been directed at symptom relief 
rather than pathophysiology of the condition, which is hetero-
genous and poorly understood.
1 I read the recent articles by Kim 
et al.
2 about the tegaserod effects on IBS with great interest. The 
efficacy and safety of tegaserod have been demonstrated by sev-
eral large randomized controlled trials.
3,4 However, tegaserod 
was taken off the market by a high chance of having a myocardial 
infarction, stroke or angina.
5 
Kim et al.
2 showed the efficacy of 5-hydroxytryptamine 4 
(5-HT4) agonist in Korean women with IBS with constipation. 
In this study, tegaserod showed the relief of overall IBS symp-
toms such as abdominal pain/discomfort, number of bowel move-
ments and stool consistency. They used the composite score of 
symptom frequency and severity as an endpoint in treatment of 
IBS. The previously published pharmaceutical trial for IBS have 
used “adequate relief of abdominal pain and discomfort” or 
“satisfactory relief of IBS symptoms” as their primary outcome 
measure which led to approvals for alosetron and tegaserod by the 
Food and Drug Administration (FDA).
6 An alternative method 
for defining a responder in an IBS treatment trial is to ask pa-
tients to report the frequency and severity of all IBS symptoms. 
Kim et al.
2 showed the adequate symptom relief and good correla-
tion between symptom composite score and IBS-QOL, which 
might show the usefulness of Korean IBS-QOL in IBS ther-
apeutic trial. However, it is not clear whether reduction of 
sum-score of 22.5/96 (23.5%) was enough to define a responder. 
They conducted this trial as open arm without placebo control. 
The FDA have recommended investigators to provide rules, a 
priori, which allow classification of each participant as a res-
ponder or non-responder for the primary outcome.
7 The secon-
dary outcome is used to strengthen the results by showing con-
cordance between individual symptoms and the primary outcome 
measure, addressing the mechanism of the intervention, and as-
sessing the safety.
6 Kim et al.
2 also proposed QOL to be included 
as a therapeutic outcome. 
Recently, there are many pharmaceutical trials including the 
next generation 5-HT agonists, such as Prucalopride, TD-5108, 
and ATI-7505 in IBS.
8 I am hoping for the present study to 
strengthen the pharmaceutical research in IBS. The primary out-
come variables provide the basis for judging the success or failure 
of an intervention, therefore, further studies on the outcome 
measurements in IBS drug trials, which can properly quantify 
drug responses, are warranted. 
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Reply.  We appreciate the comments from Dr. Hye-Kyung 
Jung. There have been several issues in clinical trials on irritable 
bowel syndrome (IBS) such as duration of trial, study design, on 
demand or repeated cycles of treatment, and optimal efficacy 
endpoint.
1,2 Among these, optimal endpoint issue is one of the 
most important factors to prove efficacy of therapeutic agent in a 
clinical trial,
3 however, widely accepted and validated outcome Letters to the Editors or Brief Communication
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measures is unavailable at present. Contrary to other gastro-
intestinal diseases such as gastroesophageal reflux disease or in-
flammatory bowel disease which are diagnosed and assessed by 
endoscopy, laboratory, and radiologic evaluation, successful 
treatment of IBS in outpatient office or assessment of  effect in 
IBS clinical trial could be measured only by symptom 
improvement.
4 
Binary endpoints, such as adequate relief and satisfactory re-
lief, have been used most commonly as primary endpoint in most 
IBS clinical trials. However there is a question whether it is 
enough as primary endpoint
5,6 therefore it should be reinforced 
by secondary (supportive) efficacy endpoints in the clinical 
research. Although IBS symptom and quality of Life (QOL) 
score could be used as secondary endpoint, the utility of QOL 
score in IBS clinical trial has not been explored as satisfactory
7 
and some authors suggest that QOL score should be considered 
as a tertiary endpoint.
4 
One of the important purposes of our study was to validate 
the usefulness of QOL as an endpoint and we found that QOL 
score was comparable to symptom score in IBS clinical trial. 
QOL provides important information to clinicians about the as-
pects of health care that “actually get to the patient”
8 and The 
European Agency for the Evaluation of Medicinal Product and 
Rome III committee emphasized QOL assessments as important 
secondary outcomes.
2,9 
The problem is that there has been no consensus about the 
definition of responder in the  outcomes by symptoms or QOL 
scoring system. We were also troubled with the definition of 
“clinically meaningful change” in scoring system when we de-
signed our study protocol. The magnitude of score changes 
which means clinically important improvement in individual 
symptom or QOL has not been defined in IBS trials.
2 Some 
studies considered as little as 10% reduction in visual analog scale 
rating of symptom severity
10 or 1 step on 7-step ordinal scale
9 as 
clinically meaningful, whereas other studies used 50% reduction 
in an aggregate symptom severity index
11 or questionnaire.
5 A 
statistically significant p-value also does not imply whether a par-
ticular finding is “clinically meaningful change.” 
Therefore we recommend clinical researchers to use QOL as 
an endpoint in IBS clinical trials and hope that further studies 
will be carried out to figure out what is the magnitude of 
“clinically meaningful change” in symptoms and QOL scoring 
system. 
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